Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 9;386(23):2243-2245.
doi: 10.1056/NEJMc2202061. Epub 2022 May 4.

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

Glenda Gray  1 , Shirley Collie  2 , Ameena Goga  1 , Nigel Garrett  3 , Jared Champion  2 , Ishen Seocharan  1 , Lesley Bamford  4 , Harry Moultrie  5 , Linda-Gail Bekker  6
Affiliations

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

Glenda Gray et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Vaccine Effectiveness against Severe Covid-19 during a Surge of the Omicron Variant in South Africa (November 15, 2021, to January 14, 2022).
Shown is the estimated effectiveness of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) and the Ad26.COV2.S vaccine (Johnson & Johnson–Janssen) against severe Covid-19, which was defined as disease resulting in hospitalization or admission to an intensive care unit (ICU) or to high care (the practice of locating patients’ beds close to the nursing station for 24-hour observation). Effectiveness data are shown according to the time period after the administration of the second dose of vaccine. If no value is provided for a specific time period in either vaccine group, data were not collected for that vaccine during that time period. 𝙸 bars indicate 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. December 17, 2021. (https://www.medrxiv.org/content/10.1101/2021.12.08.21267417v3). preprint.
    1. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med 2022;386:494-496. - PMC - PubMed
    1. Bekker L-G, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet 2022;399:1141-1153. - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021;385:585-594. - PMC - PubMed
    1. Madhi S, Kwatra G, Myers J, et al. South African population immunity and severe Covid-19 with Omicron variant. December 21, 2021. (https://www.medrxiv.org/content/10.1101/2021.12.20.21268096v1). preprint.

Supplementary concepts